Saturday, July 11, 2026

pharma · Androgenetic Alopecia · Acute Myocardial Infarction

Dong Wang

Dong Wang is a pharma organization headquartered in CN. Primary therapeutic focus areas include Androgenetic Alopecia, Acute Myocardial Infarction, Type 2 Diabetes Mellitus, Postmenopausal Osteoporosis, Alzheimer's Disea

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
8
Drugs
13
Patents
0
Clinical program

evogliptin

Phase 3 · small molecule · Type 2 Diabetes Mellitus

evogliptin for Type 2 Diabetes Mellitus is a Phase 3 program (small_molecule) at Dong Wang with 1 ClinicalTrials.gov record(s).

← All Dong Wang projects Phase 3 small molecule completed

Internal code DA1229_DMC_III

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Dong Wang
Phase
Phase 3
Modality
small_molecule
Indication
Type 2 Diabetes Mellitus
Status
completed
Trials
1

Clinical trials